ChromaDex Licenses Patent for Topical Pterostilbene

Nov 7, 2013 | Contact Author | By: Katie Anderson
Contact the Author
Save
This item has been saved to your library.
View My Library
(click to close)
Save to My Library
Title: ChromaDex Licenses Patent for Topical Pterostilbene
pterostilbenex skin carex antioxidantx blueberriesx agingx
  • Article
  • Keywords/Abstract

Keywords: pterostilbene | skin care | antioxidant | blueberries | aging

Abstract: ChromaDex Corp. is expanding the use of its pterostilbene technology in skin care with a recent patent licensing. It has licensed from Green Molecular, S.L. exclusive worldwide patent rights related to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage or injuries, including those relating to aging and exposure to the sun.

ChromaDex Corp. is expanding the use of its pterostilbene technology in skin care with a recent patent licensing. It has licensed from Green Molecular, S.L. exclusive worldwide patent rights related to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage or injuries, including those relating to aging and exposure to the sun.

The acquisition brings the total number of patents and patents pending relating to pterostilbene owned by ChromaDex to eight. This is the second acquisition made by ChromaDex of worldwide patent rights for pTeroPure associated with skin care. In September 2011, the Company entered into an agreement with the University of California, Irvine, for the exclusive rights to a joint patent application filed by ChromaDex and the University.

"We intend to continue our strategy to build intellectual property around our ingredients. By building a robust skincare IP portfolio, we are positioning to become a meaningful provider of patent protected innovative ingredient technologies to this growing multi-billion dollar market place," noted Frank Jaksch, founder and CEO of ChromaDex.

"I am excited to have this collaboration with ChromaDex. Pterostilbene, as well as its possible association with other structurally-related natural polyphenols, has multiple applications in Biomedicine. Working with ChromaDex will allow for pterostilbene's cosmetic and pharmaceutical applications in skin care and pathology to reach the market," added Jose M. Estrela, PhD, research director of Green Molecular.

The company's pTeroPure is a nature identical form of pterostilbene, an antioxidant found in blueberries. It was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. In September 2012, ChromaDex announced findings from a Phase 2/3 trial at the University of Mississippi Medical Center demonstrating that pTeroPure significantly reduced blood pressure in adults. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols,  allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting heart health, cognitive function, anti-aging, weight loss and other metabolic disorders. The amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits.